Regulatory Pfizer, Arvinas join SERD club with Veppanu approval PharmaphorumArvinas and Pfizer's Veppanu is the first PROTAC - and third oral SERD for breast cancer - to be approved by the FDA.OncologyRead full story pharminent May 4, 2026 (Last updated: May 4, 2026) Pharmaphorum Arvinas and Pfizer’s Veppanu is the first PROTAC – and third oral SERD for breast cancer – to be approved by the FDA. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Novartis unveils North Carolina API plant as final piece of $23B US expansionNext: Novo Nordisk to launch Ozempic for type 2 diabetes in US Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
